| Name | Title | Contact Details |
|---|
Aktis Oncology is a biotechnology company pioneering the discovery and development of a new class of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers.
CalciMedica is a privately-held, clinical stage biotechnology company focused on CRAC channel drug discovery and development for the treatment of acute and chronic inflammatory diseases.
Pharmexa-Epimmune Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
AnaptysBio is a privately-held antibody development company focused on novel programs in immuno-oncology and inflammation. The Company`s first-in-class proprietary pipeline includes ANB020, an anti-IL-33 antibody for the treatment of severe adult asthma and peanut allergy, and ANB019, an anti-IL-36 receptor antibody for the treatment of generalized pustular psoriasis. AnaptysBio`s SHM-XEL platform has pioneered the use of in vitro somatic hypermutation for antibody discovery and optimization, which replicates key features of the human immune system and overcomes limitations of prior antibody technologies. AnaptysBio has previously announced partnerships with several biopharmaceutical companies, including Novartis, Gilead, Celgene, Momenta and TESARO.
Lyophilization Services of New England is a Bedford, NH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.